Floatz logo

Mannitol

Head Injury

Massachusetts General HospitalSmall moleculePhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Head Injury cohort.

Asset / SponsorPhaseRating
Aspirin
Hadassah Medical Organization
Phase 4BB
Oxygen
Jay C. Buckey Jr.
Phase 4BB
Sodium Lactate
Institut d'Anesthesiologie des Alpes Maritimes
Phase 2/3B
Sufentanyl
Pierre-Julien CUNGI
Phase 2CCC
(±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone
Pierre-Julien CUNGI
Phase 2CCC
Rosuvastatin
Universidad Autonoma de San Luis Potosí
Phase 1/2CCC
Nepenthe
Dalhousie University
Phase 1/2CCC
Red Blood Cells
ThermoFisher Scientific Brahms Biomarkers France
N/AD

Same molecule, other indications

Mannitol is also rated in:

cystic fibrosisActive
BB
Indicative · Phase 4
69 / 100
View asset →
traumatic brain injuryActive
BB
Indicative · Phase 4
65 / 100
View asset →
anaplastic astrocytomaActive
B
Indicative · Phase 2
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →